# Vystar Corp > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Vystar Corp). ## Overview Vystar Corp is a U.S.-based company built around two product families: Vytex natural rubber latex materials and RxAir UV-C air purification devices. Its business combines materials development, product commercialization, and licensing/distribution activities across industrial, healthcare, and consumer-oriented end markets. ## Products & services • Vytex natural rubber latex materials • Vytex dry rubber development • RxAir residential air purifiers • RX400 and RX800 FDA-cleared air purifiers • ViraTec replacement cartridges • RxAir commercial air purifier models - **Vytex natural rubber latex** (45%) — Ultra-low protein latex and related rubber materials used in dipped products and other latex applications. - **RxAir air purifiers** (35%) — UV-C filterless air purification devices sold for residential, healthcare, and commercial use. - **Replacement cartridges and accessories** (10%) — Replacement cartridges and related consumables for previously sold RxAir units. - **Licensing and distribution arrangements** (10%) — Market development, distribution, and license-based commercialization of Vytex and related technologies. - Vytex natural rubber latex materials - Vytex dry rubber development - RxAir residential air purifiers - RX400 and RX800 FDA-cleared air purifiers - ViraTec replacement cartridges - RxAir commercial air purifier models ## Customers Vystar sells to manufacturers that use natural rubber latex in dipped goods and other rubber-intensive applications, especially where low-protein or specialty latex properties matter. Its RxAir products are sold through distributors, online channels, and retail outlets to residential buyers, healthcare users, and commercial customers seeking UV-C air purification. The company also serves replacement-part buyers for installed RxAir units and trial customers evaluating Vytex materials for manufacturing use. - **Industrial latex manufacturers** (primary) — Buy Vytex materials for dipped products and other latex applications where protein content and material performance matter. - **Healthcare and medical customers** (primary) — Buy RxAir units for air purification in environments that value germicidal UV-C performance and FDA-cleared products. - **Residential consumers** (secondary) — Buy RxAir residential purifiers for home air cleaning without traditional filters. - **Commercial and institutional buyers** (secondary) — Buy larger or commercial RxAir units for offices, facilities, and other shared spaces. - **Replacement-part customers** (emerging) — Buy ViraTec cartridges for previously sold units, supporting the installed base. - Latex product manufacturers seeking ultra-low protein materials - Dipped goods producers running manufacturing trials - Residential buyers of filterless UV air purifiers - Healthcare and medical customers using FDA-cleared units - Commercial buyers needing air purification for shared spaces - Installed-base customers buying ViraTec replacement cartridges ## Geography Vystar is headquartered in the United States and its commercial activity is centered there, including product development, manufacturing coordination, and domestic sales channels. The company also references contract manufacturing and production options in other geographies for Vytex supply lines, which can affect sourcing, logistics, and tariff exposure. Its customer reach is broader than one country, but the available disclosures emphasize U.S.-based operations and North American market needs. - Headquartered and primarily operated in the United States - RxAir is sold through U.S. distributors, online, and retail channels - Vytex commercialization includes North American market needs - Contract manufacturing may be placed based on geographic demand - Trade policy and China tariffs can affect sourcing and costs ## Strategy Vystar’s strategy centers on commercializing Vytex through trials, distribution partnerships, and licensing while expanding RxAir through newer product versions and broader channel coverage. It is also pursuing structural options for its divisions, including potential spinouts, sales, or other transactions, to unlock value and focus capital on the most scalable opportunities. Product development remains important, with efforts aimed at new air purifier formats and additional Vytex applications. - **Commercialize Vytex through trials and licensing** (medium-term) — Vytex needs customer adoption and manufacturing validation to become a scalable materials business. - **Expand RxAir product reach** (short-term) — Broader product availability and channel coverage can support recurring device and cartridge sales. - **Pursue corporate transactions for divisions** (short-term) — Spinouts or sales may help separate businesses with different capital needs and commercialization paths. - Expand Vytex through trials and manufacturing-scale adoption - Grow RxAir sales through distributors, online, and retail channels - Monetize technology through license fees and distribution agreements - Develop new product formats such as smaller RxAir models - Evaluate spinouts, sales, or other transactions for divisions ## Risks Vystar faces execution risk because its businesses depend on customer trials, commercialization milestones, and continued access to financing. It also has exposure to tariff and supply-chain disruption, product adoption uncertainty, and the challenge of scaling niche technologies into repeatable revenue streams. As a small company with limited operating scale, delays in product acceptance or capital formation can materially affect continuity and growth. - **Going concern and liquidity risk** [critical] — The company depends on external financing and product monetization to fund operations. - **Commercialization risk for Vytex** [high] — Vytex relies on trials, customer validation, and manufacturing-scale adoption before it can generate durable demand. - **Product adoption risk for RxAir** [high] — Air purifier sales depend on channel execution, regulatory positioning, and customer acceptance of UV-C technology. - **Tariff and supply-chain risk** [medium] — Trade policy and import tariffs can raise input costs and disrupt sourcing or contract manufacturing decisions. - Going-concern and financing risk due to limited cash resources - Customer trial risk for Vytex and delayed manufacturing adoption - Tariff and import cost exposure, including China-related trade actions - Product commercialization risk for new RxAir models and prototypes - Dependence on a small number of product lines and channels ## Accounting Vystar’s reported results are sensitive to revenue timing, product mix, and the accounting treatment of stock-based compensation and other operating expenses. Because the company has limited scale and uses a going-concern basis, estimates around recoverability, financing, and transaction structure can materially affect reported results. Investors should also watch how discontinued operations, divestitures, and any future spinouts change comparability across periods. - **Revenue recognition timing** — Quarterly comparability - **Stock-based compensation** — Operating expense and net loss - **Going-concern disclosures** — Financial statement presentation and risk disclosure - **Discontinued operations and divestiture accounting** — Comparability across periods - Revenue timing can swing with bulk sales, trials, and channel orders - Stock-based compensation is a large operating expense item - Going-concern assumptions affect valuation and disclosure judgments - Discontinued operations can distort period-to-period comparisons - Potential spinouts or asset sales may change consolidation scope --- *Last updated: 2026-04-29T05:08:49.220391+00:00*